Ondansetron Injection 4 mg/ml is a selective 5-HT₃ receptor antagonist used to prevent and manage nausea and vomiting in the following clinical settings:
1. Chemotherapy-Induced Nausea and Vomiting (CINV)
2. Radiotherapy-Induced Nausea and Vomiting (RINV)
3. Postoperative Nausea and Vomiting (PONV)
Precautions while taking Ondansetron Injection USP 4 mg/ml
Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT₃ receptor antagonists.
Respiratory events should be treated symptomatically, and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.
Ondansetron prolongs the QT interval in a dose-dependent manner. Avoid ondansetron in patients with congenital long QT syndrome.
Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, or bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.
Hypokalemia and hypomagnesemia should be corrected prior to ondansetron administration.
Concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted; appropriate observation of the patient is advised.
As ondansetron is known to increase large bowel transit time, patients with signs of subacute intestinal obstruction should be monitored following administration.
In patients with adenotonsillar surgery, prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.
Pediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.
Dosages of Ondansetron Injection 4 mg/ml
Adults:
The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of ondansetron should be flexible in the range of 8-32 mg a day and selected as shown below.
Emetogenic chemotherapy and radiotherapy
For patients receiving emetogenic chemotherapy or radiotherapy, ondansetron can be given either by oral or intravenous administration.
For most patients receiving emetogenic chemotherapy or radiotherapy, Ondansetron 8 mg should be administered as a slow intravenous injection (in not less than 30 seconds) or as a short-time intravenous infusion over 15 minutes immediately before treatment, followed by 8 mg orally every twelve hours.
To protect against delayed or prolonged emesis after the first 24 hours, oral treatment with ondansetron should be continued for up to 5 days after a course of treatment.
Highly emetogenic chemotherapy
For patients receiving highly emetogenic chemotherapy, e.g., high-dose cisplatin, ondansetron can be given by oral, rectal, or intravenous administration. Ondansetron has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy:
– A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) immediately before chemotherapy.
– A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) immediately before chemotherapy, followed by two further intravenous injections (in not less than 30 seconds) of 8 mg four hours apart, or by a constant infusion of 1 mg/hour for up to 24 hours.
– A maximum initial intravenous dose of 16 mg diluted in 50-100 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes immediately before chemotherapy. The initial dose of ondansetron may be followed by two additional 8 mg intravenous doses (in not less than 30 seconds) four hours apart.
A single dose greater than 16 mg must not be given due to the dose-dependent increase of QT-prolongation risk. The selection of dose regimen should be determined by the severity of the emetogenic challenge.
The efficacy of ondansetron in highly emetogenic chemotherapy may be enhanced by the addition of a single intravenous dose of dexamethasone sodium phosphate, 20 mg, administered prior to chemotherapy.
To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with ondansetron should be continued for up to 5 days after a course of treatment.
Constipation, Headache, Uncommon: Seizures, movement disorders, Rare: Dizziness predominantly during rapid IV administration, local IV injection site reactions.
Store below 30°C and protect from light.
Keep out of reach of children.
Ondansetron Injection USP 4 mg/ml is available as 4 ml in a clear glass ampoule. Such 05 glass ampoules in a unit carton with a pack insert.
Contact us directly to receive full information on the product, the formulation, the science behind it, stability data, and more. Our Business Development Manager is a click away.
Questions are useful tools, they open lines of communication; give us information; improve interactions, facilitate analysis, and many more.
A pharma CMO is a special kind of an organization, offering contract manufacturing services to pharmaceutical companies for various kinds of drug formulations.
Reduce overall costs and time to market :
Contract manufacturers already have the needed infrastructure and technical staff, so working with a CMO or CDMO can decrease the cost of manufacturing your pharmaceutical products.
Scalability and flexible production capacity :
You can produce what you need when you need it without worrying about excess capacity. Additionally, CMOs understand the importance of quality and compliance, so you don't have to sacrifice safety for scalability.
Save on upgrading and maintaining equipment :
If you have your manufacturing facility, you’ll have to pay to upgrade your equipment as technology advances—which can get expensive. A CMO/CDMO’s only function is to make and distribute products, so part of their core business responsibility is to update their equipment whenever needed and perform maintenance.
Ease supply chain issues :
During the pandemic, there were several instances of supply chain issues, including medicine shortages. CMOs are generally better equipped than startups to handle a supply chain crisis.
Bandwidth to focus on core competencies
When your company resources aren’t directly allocated to manufacturing and distribution, you have more time to focus on other tasks, like marketing your new drug, researching, or working on drug discovery.
We have 7+ manufacturing sites with a minimum of WHO GMP certification and other country-specific approvals like NAFDAC approved, PPK Kenya Approved, TFDA Tanzania Approved, EU-GMP Approved.
We have below manufacturing capacity:
For Tablet, Capsule, and soft gel: up to 1 million units per shift
For Syrup: up to 0.05 Million per shift
For Ampoule and Vial: up to 0.1 million units per shift
For Ointment and Cream: up to 0.1 million units per shift
For Suppository: 0.1 Million units per shift
